Douglas Grossman, MD, PhD, is an investigator in Huntsman Cancer Institute's Melanoma Program and an associate professor in the Department of Dermatology at the University of Utah School of Medicine. He is a co-leader of the Cell Response and Regulation Program. He sees patients at risk for melanoma and non-melanoma skin cancer, with a special interest in patients who have a personal or family history of melanoma; numerous and/or atypical moles (nevi); a personal history of basal or squamous cell carcinoma; or a history of excessive sun exposure. Grossman runs the Mole Mapping Program at Huntsman Cancer Institute.

Grossman's lab studies the regulatory mechanisms of apoptosis, or programmed cell death, in melanocytes and keratinocytes, and dysregulation of apoptosis in both melanoma and non-melanoma skin cancer. In addition, they study nevus senescence and the role of UV-induced oxidative stress/damage in the development of melanoma. In collaborative studies with other investigators at Huntsman Cancer Institute, they are developing novel antioxidants to be used as chemopreventive agents in patients at risk for melanoma.

Grossman received his MD and PhD from Baylor College of Medicine, completed an internship at Yale-New Haven Hospital, and completed a dermatology residency at Yale. He remained at Yale for a research fellowship in cancer biology, and then joined Huntsman Cancer Institute and the University of Utah School of Medicine faculty in 2001.